Clinical Trial Update: A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases [Phase 2]

View source ↗

Summary

Phase II study of cabozantinib (XL184) in castration-resistant prostate cancer with visceral metastases has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Edwin Posadas, MD | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-27